Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase NA 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 967Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Leukemia 486Myelodysplastic Syndromes 375Lymphoma, Non-Hodgkin 347Lymphoma 297Lymphoma, Mantle-Cell 263Hematologic Neoplasms 260Lymphoma, Follicular 256Lymphoma, Large B-Cell, Diffuse 253Burkitt Lymphoma 232Lymphoma, B-Cell, Marginal Zone 227Recurrence 216Hodgkin Disease 182Multiple Myeloma 172Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Lymphoma, Large-Cell, Immunoblastic 158Leukemia, Myelomonocytic, Chronic 153Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Waldenstrom Macroglobulinemia 123Lymphoma, T-Cell, Cutaneous 116Neoplasms 112Lymphoma, Large-Cell, Anaplastic 111Blast Crisis 105Congenital Abnormalities 104Immunoblastic Lymphadenopathy 98Mycosis Fungoides 97Sezary Syndrome 96Myeloproliferative Disorders 92

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hypereosinophilic Syndrome × Other hematologic neoplasm × Clear all
NCT01066468 2012-03-13

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Novartis

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡